# Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA: Phase 2 study closed enrollment, 70 enrolled (Pulmonary Disease, Chronic Obstructive, COPD)

**Score:** 90/100

| Field | Value |
|---|---|
| Sponsor | Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA |
| Sponsor type | Industry (pharma, biotech, medtech) |
| Study | Effect of Ensifentrine (MK-5884/RPL554) on Sputum Markers of Inflammation in Chronic Obstructive Pulmonary Disease (COPD) (MK-5884-023/RPL554-CO-207) |
| NCT ID | NCT05270525 |
| Phase | Phase 2 |
| Status | active not recruiting |
| Conditions | Pulmonary Disease, Chronic Obstructive, COPD |
| Intervention types | drug |
| Target enrollment | 70 |
| Site countries | United States |
| Posted | 2022-03-08 |
| Planned start | 2022-05-27 |
| Event | Enrollment closed (active, not recruiting) |
| Event date | 2026-11-03 |
| Last update posted | 2026-11-03 |

## Why this score
- Posted in the last two weeks.
- Industry sponsor (buys outsourced services).
- Enrollment closed: data management, monitoring and closeout ahead.
- Phase 2: multi-site, larger budget.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT05270525). Last refreshed: 2026-11-05T08:46:16.625Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.